loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Caplin Point Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Caplin Point Laboratories Ltd. 14 May 2026 14:41 PM
Result PDF

Q4FY26 & FY26 Result Announced for Caplin Point Laboratories Ltd.

Pharmaceuticals company Caplin Point Laboratories announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations for Q4FY26 stood at Rs 600.16 crore, representing a YoY increase of 19.4% compared to Rs 502.45 crore in Q4FY25 and a QoQ growth of 10.6% from Rs 542.77 crore in Q3FY26.
  • Total Income for the quarter was Rs 628.52 crore, reflecting a YoY growth of 19.0% as against Rs 528.19 crore and a 9.0% increase QoQ from Rs 576.45 crore.
  • Profit Before Tax (PBT) for Q4FY26 reached Rs 213.44 crore, up 20.8% YoY from Rs 176.67 crore and up 4.7% QoQ from Rs 203.89 crore in Q3FY26.
  • Net Profit for the quarter (PAT) stood at Rs 172.88 crore, marking a 19.0% increase YoY compared to Rs 145.28 crore and a 4.2% increase QoQ from Rs 165.86 crore.
  • For the full year ended March 31, 2026, Revenue from Operations was Rs 2,187.19 crore, a growth of 12.9% YoY from Rs 1,937.47 crore in FY25.
  • Annual Total Income for FY26 was Rs 2,302.73 crore, showing a 13.2% increase over Rs 2,033.90 crore in FY25.
  • Annual Net Profit (PAT) for FY26 stood at Rs 649.73 crore, registering a 20.1% growth from Rs 541.09 crore in FY25.
  • Earnings Per Share (EPS) for Q4FY26 was Rs 22.38 (Basic), compared to Rs 18.75 in Q4FY25. For FY26, Basic EPS reached Rs 84.36, up from Rs 70.57 in FY25.

Standalone Financial Highlights:

  • Revenue from Operations for Q4FY26 was Rs 191.36 crore, reflecting a 10.2% YoY growth from Rs 173.61 crore in Q4FY25 and a 1.1% QoQ increase from Rs 189.22 crore in Q3FY26.
  • Total Income for the quarter reached Rs 252.44 crore, compared to Rs 214.86 crore in Q4FY25 and Rs 220.95 crore in Q3FY26.
  • Profit Before Tax (PBT) for Q4FY26 stood at Rs 137.72 crore, a 25.0% increase YoY as against Rs 110.16 crore and a 17.7% increase QoQ from Rs 117.01 crore.
  • Net Profit (PAT) for the quarter was Rs 109.50 crore, up 26.6% YoY from Rs 86.50 crore and up 25.5% QoQ from Rs 87.28 crore.
  • For FY26, Standalone Revenue from Operations was Rs 738.33 crore, compared to Rs 752.41 crore in FY25.
  • Annual Standalone Net Profit (PAT) for FY26 was Rs 396.58 crore, representing a 16.8% increase YoY from Rs 339.49 crore.

Business Highlights:

  • Geographical Segment Performance:
    • Rest of the World: This segment recorded a revenue of Rs 470.25 crore in Q4FY26 and Rs 1,733.79 crore For FY26. Segment results (PBT) for the year reached Rs 631.20 crore.
    • USA: This segment generated a revenue of Rs 129.91 crore in Q4FY26 and Rs 453.40 crore For FY26. Segment results (PBT) for the year stood at Rs 56.05 crore.
  • Interim Dividend: The Board of Directors declared an Interim Dividend of Rs 4.00 (200%) per equity share of face value Rs 2 each for the financial year ended March 31, 2026.
  • Caplin Steriles USA Inc (CSU) Performance: CSU completed its first full year of operations with approximately USD 11 million in revenue and 26.2% EBITDA, achieving profitability and self-sustaining cash flow within its first year. CSU has launched 30 products to date with plans to launch 15 more in the current year.
  • Product Approvals and Pipeline: The company received 10 ANDA approvals in FY26 and acquired 15 ANDAs from third parties, bringing the total ANDA tally to 59, an increase of 25 ANDAs over FY25. In Mexico, the company received approvals for 25 products with a pipeline of over 120 products to be filed within 18 months.
  • Capacity Expansion: The company is expanding its IV Bag line capacity to 3X its current size. Construction of the COL-II facility is expected to be completed by December 2026, which will house 5 Injectable, Ophthalmic, and BFS lines.
  • Strategic Growth and Capex: Caplin Point has allocated an enhanced Capex budget of approximately Rs 1,000 crore for investment projects, with about 50% nearing completion.
  • Latin America Update: The company entered the Brand Marketing CNS segment in three Latin American markets, with plans to expand to two more in 2027.
  • Labour Code Impact: The company assessed the implications of the New Labour Codes, resulting in an increase in employee benefit obligations (gratuity and compensated absences) aggregating to Rs 1.39 crore (Consolidated) and Rs 0.84 crore (Standalone).

C.C. Paarthipan, Chairman, said: The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delivered strong financial performance, with sustained margins, healthy cash generation, and consistent growth across our key markets. The strength of our unique end-to-end business model is showcased clearly by the consistency of these numbers, at a larger base also.

Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth.

During the year, we made significant investments in building future capabilities — across manufacturing, automation, compliance strengthening, backward integration, product development, and regulatory filings. Our progress in Oncology, APIs, and complex dosage forms such as Pre-Filled Syringes and BlowFill-Seal technology, positions us well for the next phase of growth. Importantly, these investments are being made while maintaining strong cash flows and a robust balance sheet. We remain debt-free and will continue to remain so.

We are also encouraged by the early success of Caplin Steriles USA, our front-end initiative in the US, which achieved profitability within its first year of operations — an outcome that reflects both execution discipline and the strength of our product selection. This was done without a de-growth in our B2B business, which shows our discipline in capacity utilization and ensuring consistent supply across segments.

As we look ahead, our focus remains clear: to build a diversified and resilient business across geographies, deepen our presence in complex and differentiated products, and continue investing in quality, compliance, and automation. Initiatives such as our backward integration program, expansion into new technologies, and digital transformation efforts will play a critical role in strengthening our competitive position.

While we remain optimistic about the opportunities ahead, we will continue to approach growth with prudence and discipline, staying aligned with our core principles of sustainable and profitable expansion. I would like to thank our employees for their dedication, our partners for their continued trust, and our shareholders for their unwavering support.

Result PDF

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q3FY26 results

  • Revenue: Rs 542.8 crore against Rs 493 crore during Q3FY25, change 10%.
  • EBITDA: Rs 223.4 crore against Rs 193.7 crore during Q3FY25, change 15%.
  • EBITDA Margin: 38.7% for Q3FY26.
  • PBT: Rs 203.9 crore against Rs 177.3 crore during Q3FY25, change 15%.
  • PBT Margin: 35.4% for Q3FY26.
  • PAT: Rs 165.9 crore against Rs 140.1 crore during Q3FY25, change 18%.
  • PAT Margin: 28.8% for Q3FY26.

C.C. Paarthipan, Chairman, said: Our performance in Q3FY26 and 9MFY26 reflects far more than financial outcomes - it reflects the quiet compounding of a long-term strategy built on being different from others. We have sustained our strong margins, expanded profitability, and delivered robust cash generation, all while continuing to invest heavily in capacity, technology, people and future platforms. This balance between growth and prudence remains central to how we think about building enduring value.

In Emerging Markets, our end-to-end business model continues to create a powerful competitive moat, as we create enriching value on both sides by catering to the bottom of the pyramid. By keeping products closer to customers, expanding local presence, and broadening our portfolio through internal development and global partnerships, we are steadily deepening relevance in markets that value reliability, affordability, and long-term commitment. Our progress in Latin America, the scaling of GLP-1 products, the acceleration of our “China 2.0” strategy, and our investments in oncology and APIs reinforce our belief that resilience is built through thoughtful vertical integration and geographic diversification.

In the US and other regulated markets, Caplin Steriles continues to move up the complexity curve — combining strong compliance, first-cycle approvals, advanced drug-delivery platforms, and increasing automation. The early success of our US front end, along with investments in pre-filled syringes, BFS, and “Visual Integration” project positions us well for the next phase of growth. As we look ahead, we remain guided by a simple principle: build compliance through automation, expand capabilities ahead of demand, and grow businesses that can compound sustainably. With a strong balance sheet, a deep pipeline, and a clear strategic roadmap, we are confident in our ability to create lasting value for patients, partners, and shareholders alike.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q2FY26 results

  • Revenue from Operation: Rs 534.0 crore compared to Rs 483.1 crore during Q2FY25, change 10.5%.
  • EBITDA: Rs 219.5 crore compared to Rs 185.5 crore during Q2FY25, change 18.3%.
  • EBITDA Margin: 38.9% for Q2FY26.
  • PBT: Rs 201.0 crore compared to Rs 168.5 crore during Q2FY25, change 19.3%.
  • PAT: Rs 160.2 crore compared to Rs 130.8 crore during Q2FY25, change 22.5%.

C.C. Paarthipan, Chairman, said: "Consistency has been the cornerstone of Caplin’s journey. We are pleased to report another strong set of results, fully aligned with our long-term growth path and guidance. Our unwavering focus on cashflows, profitability, and revenue growth continues across all segments of the business, complemented by an equally strong commitment to compliance and governance.

We are leveraging our deep understanding of smaller Latin American markets through our subsidiaries in the front end, together with our R&D and supply chain excellence at the back end, to create a powerful foundation for expansion into larger markets such as Mexico, Chile, Colombia, and eventually Brazil.

Our relentless emphasis on compliance and operational productivity continues to drive robust growth in regulated markets like the U.S. and Canada, and we expect this segment to represent an even greater share of our business in the coming years. Meanwhile, our China 2.0 strategy positions us to fast-track entry into high-potential areas such as Biosimilars and Peptides — segments traditionally dominated by larger players.

The building blocks we are putting in place from now and over the next couple of year will set Caplin on a strong, multi-year growth trajectory, underpinned by the same consistency, discipline, and performance metrics that have defined us thus far."

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q1FY26 results

  • Gross Margin for Q1FY26 is 61.7% vs 59.6% in Q1FY25 aided by new product launches across existing and new markets.
  • EBITDA Margin for Q1FY26 is at 37.7% vs 35.7% in Q1FY25.
  • Basic EPS increased by 23.1% to Rs 20.10 in Q1FY26 compared to Rs 16.32 in Q1FY25.
  • Cash Flow from Operations in Q1FY26 is Rs 118 crore vs Rs 96 crore in Q1FY25.
  • Free Cash Flow is Rs 53 crore (after Capex investment of Rs 65 crore) in Q1FY26 as compared to Rs 59 crore (after capex investment of Rs 37 crore) in Q1FY25.
  • Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for Q1FY26 is in the range of 79% and 21% respectively.
  • CSL’s Revenue composition demonstrates a balanced mix of Product Supply and Milestone Profit Share, with the split for Q1FY26 in the range of 85% and 15% respectively.
  • As of 30th June 2025, Inventories are at Rs 324 crore - 56% Stock at the warehouses, close to the customer; In Transit 13%; 31% in India. Receivables are at 114 days.
  • As of 30th June 2025, Free Cash reserves are at Rs 1,237 crore and Total Liquid Assets at Rs 2,207 crore.

C.C. Paarthipan, Chairman, said: "We’re putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows."

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Gross Margin: 60% vs. 56.6% in Q4FY24 — aided by new product launches across existing and new markets.
  • Revenue from Operations: Rs 502.5 crore vs. Rs 453.2 crore in Q4FY24 — up 10.9% YoY.
  • EBITDA: Rs 193.8 crore vs. Rs 162.5 crore in Q4FY24 — up 19.2% YoY.
  • EBITDA Margin: 36.7% vs. 34.5% in Q4FY24
  • Profit After Tax (PAT): Rs 145.3 crore vs. Rs 121.2 crore in Q4FY24 — up 19.8% YoY.

FY25 Financial Highlights:

  • FY25 Total Revenue at Rs 2034 crore; an increase of 15.5% YoY
  • FY 25 PAT at Rs 541 crore; (Growth of 17.3% over FY24)
  • EBITDA Margin: 36.5% vs. 35.1% in FY24 
  • Basic EPS increased by 17.2% to Rs 70.57 in FY25 compared to Rs 60.19 in FY24.
  • Cash Flow from Operations in FY25 is Rs 432.39 crore vs Rs 318 crore in FY24. 
  • CSL's Total revenue crosses Rs 366 crore, an increase of 15% over FY24.
  • US Market FY25 EBIDTA crosses Rs 102 crore (Growth of 71% over FY24)
  • Free Cash Reserves at Rs 1,180 crore; Liquid Assets at Rs 2,148 crore

Commenting on the performance, C.C. Paarthipan, Chairman said: "We’re delighted to close out another year with excellent Top and Bottom Line Growth, and continue our progress on being a benchmark when it comes to Cashflows. Our front end in the US is taking shape at a good pace and we expect this entity to drive strong growth for the parent company over the next few years. We’re once again focusing on getting back to Asset Light outsourcing using our Second Innings at China, with import of Peptides and Key starting materials for Biosimilars, which we plan to file and launch in our Emerging Markets where we have a significant presence already. With our API entities coming on stream in the very near future, we can truly envision Caplin being a fully integrated global Pharma player in the years to come."

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q3FY25 results

  • Revenue: Rs 493.0 crore compared to Rs 435.5 crore during Q3FY24, change 13.2%.
  • EBITDA: Rs 193.7 crore compared to Rs 159.5 crore during Q3FY24, change 21.4%.
  • PBT: Rs 177.3 crore compared to Rs 145.4 crore during Q3FY24, change 21.9%.
  • PAT: Rs 140.1 crore compared to Rs 119.8 crore during Q3FY24, change 16.9%.
  • Gross Margin for Q3FY25 is 60.4% vs 56.3% in Q3 FY24.
  • EBITDA Margin for Q3FY25 is at 36.9% vs 35.2% in Q3 FY24.
  • As of 31st December 2024, Inventories are at Rs 333 crore - 52% Stock at the warehouses, close to the customer; In Transit 18%; 30% in India.
  • Receivables is at 118 days. As of 31st December, 2024 Free Cash reserves are at Rs 1,081 crore and Total Liquid Assets at Rs 2,042 crore.

C.C. Paarthipan, Chairman, said: We’re happy to report another strong set of numbers for this quarter, underlining our sharp focus on consistency in all areas. The company has shown encouraging progress within a very short period when it comes to the launch of our own label in the US, and with consistent on-time approvals, we’re confident that this entity will deliver robust growth to the organization. We’re making good progress in our key emerging markets of Mexico and Chile, and we can start to see tangible growth from these areas in the next couple of years. The company is well positioned for continued growth in all parameters, with benchmark cashflows for multiple years to come.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced H1FY25 & Q2FY25 results

  • Gross Margin for Q2FY25 is 60.9% vs 60.0% in Q2FY24 and H1FY25 is 60.3% vs 57.4% in H1FY24, aided by new product launches across existing and new markets.
  • EBITDA Margin for Q2FY25 is steady at 36.8% vs 36.7% in Q2FY24 and H1FY25 is 36.3 % vs 35.4% in H1FY24.
  • Basic EPS increased by 16.6% to Rs 33.54 in H1FY25 compared to Rs 28.75 in H1FY24.
  • Cash Flow from Operations in H1FY25 is Rs 186 crore vs Rs 129 crore in H1FY24.
  • Free Cash Flow is Rs 109 crore (after Capex investment of Rs 77 crore) in H1FY25 as compared to Rs 50 crore (after capex investment of Rs 79 crore) in H1FY24.
  • Geographical revenue composition between Latin America & Rest of World and US for H1FY25 is in the range of 82% and 18% respectively.
  • CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone Profit Share, with the split for H1FY25 in the range of 75% and 25% respectively.
  • As of Q2FY25, Inventories are at Rs 327 crore - 50% Stock at the warehouses, close to the customer; In Transit 20%; 30% in India.
  • Receivables is at 118 days.
  • As of Q2FY25 Free Cash reserves are at Rs 1,039 crore and Total Liquid Assets at Rs 1,984 crore.

C.C. Paarthipan, Chairman, Caplin Point Laboratories, said: Consistency and Stability are key factors in the sustainability of any business. When we add our unique business model of taking the road less travelled and catering to the bottom of the pyramid, you have a potent combination. Our relentless focus towards high degree of compliance, supply chain efficiency and robustness in cashflows has led to another strong quarter, driven both by our Emerging Markets business in LatAm and our growing business in the US. We remain confident of keeping up these fundamentals in the years to come.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q1FY25 results:

  • Gross Margin for Q1FY25 is 59.6% vs 55.3% in Q1FY24.
  • EBITDA Margin for Q1FY25 is 35.7% vs 34.0% in Q1FY24, aided by new product launches.
  • Basic EPS increased by 19.8% to Rs 16.32 in Q1FY25 compared to Rs 13.62 in Q1FY24.
  • Cash Flow from Operations in Q1FY25 is Rs 96 crore (EBITDA to Cashflow conversion of 56.4%).
  • Free Cash Flow is Rs 59 crore (after Capex investment of Rs 37 Crores) in Q1FY25 as compared to Rs 37 crore (after capex investment of Rs 51 Crores) in Q1FY24.
  • Geographical revenues: Latin America and Rest of World 83%, US 17%.
  • Caplin Steriles Ltd (“CSL”) Q1FY25 Operating Revenue is at Rs 77.93 crore, with 68.9% Y-o-Y growth.
  • CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone Profit Share, with the split for Q1FY25 in the range of 74% and 26% respectively.
  • As of 30th June 2024, Inventories are at Rs 311.60 crore, Receivables is at 113 days.
  • Free Cash Reserves are at Rs 969.2 crore. Total Liquid Assets of the Company (Inventory Receivables Free Cash Reserves) are at Rs 1,849 crore as on 30th June’ 2024

Commenting on the performance, C.C. Paarthipan, Chairman said: Our company continues to be an outlier, whether its taking the road less travelled in Latin America, or focusing on our Cashflow and Bottom line rather than unsustainable or inconsistent top line growth. We’re pleased to report yet another strong set of numbers for this quarter. LatAm is a key driver of growth but we’re now also supported by strong performance from the US. As we embark on launching our own frontend in the US, we remain confident that our pattern of success through taking the road less travelled would repeat itself in the biggest markets in the world as well.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

  • Revenue from Operation: Rs 435.50 crore, increased by 17.0% compared to Q3FY23.
  • Total Revenue: Rs 452.68 crore, increased by 17.2% compared to Q3FY23.
  • Gross Profit: Rs 245.39 crore, increased by 17.9% compared to Q3FY23.
  • Gross Margin%: 56.3%, increased from 55.9% in Q3FY23.
  • EBITDA: Rs 159.46 crore, increased by 29.1% compared to Q3FY23.
  • EBITDA Margin%: 35.2%, increased from 32.0% in Q3FY23.
  • PBT: Rs 145.41 crore, increased by 30.1% compared to Q3FY23.
  • PBT Margin%: 32.1%, increased from 28.9% in Q3FY23.
  • PAT: Rs 119.82 crore, increased by 23.0% compared to Q3FY23.
  • PAT Margin%: 26.5%, increased from 25.2% in Q3FY23.

Consolidated 9MFY24:

  • Revenue from Operation: Rs 1,240.88 crore, increased by 15.2% compared to 9MFY23.
  • Total Revenue: Rs 1,290.53 crore, increased by 15.0% compared to 9MFY23.
  • Gross Profit: Rs 708.07 crore, increased by 19.8% compared to 9MFY23.
  • Gross Margin%: 57.1%, increased from 54.8% in 9MFY23.
  • EBITDA: Rs 455.86 crore, increased by 26.0% compared to 9MFY23.
  • EBITDA Margin%: 35.3%, increased from 32.2% in 9MFY23.
  • PBT: Rs 418.40 crore, increased by 27.8% compared to 9MFY23.
  • PBT Margin%: 32.4%, increased from 29.2% in 9MFY23.
  • PAT: Rs 340.19 crore, increased by 23.4% compared to 9MFY23.
  • PAT Margin%: 26.4%, increased from 24.6% in 9MFY23.

Commenting on the performance, C.C. Paarthipan, Chairman said: "Consistency has always been a key area for our company and this Quarter is no different. The company delivered strong results, reporting Revenue from Operations of Rs 436 crore, resulting in a 17% YoY growth. Net Profit amounted to Rs 120 crore, reflecting a 23% YoY growth, with margins at 27%. Approval from Colombia’s INVIMA for our Caplin Steriles site will accelerate growth in newer markets like Mexico, Chile and Colombia, reinforcing our commitment to high regulatory standards and positioning us for success. We remain committed to driving sustainable growth with strong cashflows".

 

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q1FY24 results:

  • Revenue for Q1FY24 grew by 13.1% YoY to Rs 407 crore
  • Gross margin for Q1FY24 is at 54.8%
  • EBITDA for Q1FY24 is Rs 139 crore; EBITDA margins at 34.0%
  • Q1FY24 PAT is at Rs 104 crore up 20.8% YoY
  • Cash and cash equivalents at Rs 808 crore as of June 30, 2023
  • Cash flow from operations at Rs 88 crore for Q1FY24; Capex for Q1FY24 is at Rs 51 crore; Free cash flow for the period was Rs 37 crore
  • Basic EPS grew by 21% to Rs 13.62 in Q1FY24 against Rs 11.21 in Q1FY23
  • Receivable stood at 97 days
  • Geographical breakup of sales: LATAM & ROW 88%, US 12%

Commenting on the performance, C.C. Paarthipan, Chairman, said, “We are particularly pleased with the robust growth in our Latin America business, both in terms of revenue and profitability which also resulted in robust margins. The expansion of Softgel capacity at our CP-1 site has strengthened our position in this market, with a quick payback.

Coming to the US, with a strong order book, we are optimistic about achieving 40-50% revenue growth in FY24. We aim to achieve this growth through strategic new product launches and by increasing our market share for existing products.

Overall, we remain committed to driving sustainable growth and delivering value to all our stakeholders.”

 

 

Result PDF

Trending News

Mahindra & Mahindra (M&M), which holds a 43.6% share of India’s tractor market, is expanding its focus beyond tractors to accelerate farm mechanisation

Mahindra & Mahindra (M&M), which holds a 43.6% share of India’s tractor market, is expanding its focus beyond tractors to accelerate farm mechanisation

Published on 08-Jun-2026 09:15

Tata Motors Commercial Vehicles business is increasingly focusing on non-cyclical revenue streams

Tata Motors Commercial Vehicles business is increasingly focusing on non-cyclical revenue streams

Published on 08-Jun-2026 09:14

Coal India has announced a series of business-friendly initiatives

Coal India has announced a series of business-friendly initiatives

Published on 08-Jun-2026 09:13

The Delhi government has announced plans to add 2800 air-conditioned low-floor electric buses

The Delhi government has announced plans to add 2800 air-conditioned low-floor electric buses

Published on 08-Jun-2026 09:11

Bharat Heavy Electricals Ltd has received a Notification of Award worth over Rs21000 crore

Bharat Heavy Electricals Ltd has received a Notification of Award worth over Rs21000 crore

Published on 08-Jun-2026 09:10

JK Cement has executed the mining lease for the Mahan Underground Coal Mine

JK Cement has executed the mining lease for the Mahan Underground Coal Mine located in Singrauli, Madhya Pradesh, with the Government of Madhya Pradesh. The mine covers an area of 981.75 hectares

Published on 08-Jun-2026 09:08

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app